Literature DB >> 19098456

Osteosarcoma: Conventional treatment vs. gene therapy.

Mei Lin Tan1, Peter F M Choong, Crispin R Dass.   

Abstract

Osteosarcoma (OS) remains the most common primary malignant bone cancer affecting children and adolescents. Majority of patients are subjected to surgery and chemotherapy with limited alternatives to consider. However, with increasing knowledge of the molecular pathogenesis of OS, advancements in OS therapy research fields have developed potential agents for a more targeted and localised approach to treatment. Thus, this review attempts to examine some common treatment strategies (surgery, radiotherapy and chemotherapy) employed clinically as well as recent developments in newer experimental therapy methods (gene therapy) which might potentially benefit patients.

Entities:  

Mesh:

Year:  2009        PMID: 19098456     DOI: 10.4161/cbt.8.2.7385

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  46 in total

1.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

2.  MicroRNA-126 inhibits osteosarcoma cells proliferation by targeting Sirt1.

Authors:  Jian-Qiang Xu; Ping Liu; Ming-Jue Si; Xiao-Yi Ding
Journal:  Tumour Biol       Date:  2013-07-24

3.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

4.  RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells.

Authors:  Toru Akiyama; Peter F M Choong; Crispin R Dass
Journal:  Clin Exp Metastasis       Date:  2010-04-11       Impact factor: 5.150

5.  Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.

Authors:  Zhixun Yin; Hongmei Ding; Erxing He; Jingchen Chen; Ming Li
Journal:  Cell Prolif       Date:  2016-10-05       Impact factor: 6.831

6.  Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.

Authors:  Milcah C Scott; Aaron L Sarver; Hirotaka Tomiyasu; Ingrid Cornax; Jamie Van Etten; Jyotika Varshney; M Gerard O'Sullivan; Subbaya Subramanian; Jaime F Modiano
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

7.  HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.

Authors:  Jie Chen; Jun Xia; Yong-lin Yu; Si-qun Wang; Yi-bing Wei; Fei-yan Chen; Gang-yong Huang; Jing-sheng Shi
Journal:  Tumour Biol       Date:  2013-10-05

8.  Direct anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours.

Authors:  Mei Lin Tan; Peter F M Choong; Crispin R Dass
Journal:  Cancer Cell Int       Date:  2010-03-24       Impact factor: 5.722

9.  Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.

Authors:  M Takagi-Kimura; T Yamano; M Tagawa; S Kubo
Journal:  Cancer Gene Ther       Date:  2014-02-28       Impact factor: 5.987

Review 10.  Strategies for the targeted delivery of therapeutics for osteosarcoma.

Authors:  Dennis P M Hughes
Journal:  Expert Opin Drug Deliv       Date:  2009-12       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.